窗体顶端

 

 

一、基本信息

姓名：张嘉杰                                 

职称：研究员

联系邮箱：zhangjj@smu.edu.cn

 

二、学习经历

1986.9-1990.7   湖南师范大学，化学，学士

1993.9-1996.7   华南师范大学，高分子化学与物理，硕士

2001.9-2004.7   第一军医大学，药理学，博士

 

三、拟招收博士后开展的研究方向

1.基于靶标结构的药物分子设计；

2.创新药物合成及活性评价

 

四、主要学术任职

1. 中国药理学会抗炎免疫药理学专业委员会，委员；

2. 广东省高性能计算学会专业委员会，常务理事；

3. 广东省药学会药物化学专业委员会，委员

 

五、代表性论文

1. Y Tian#, T Zhang#, L Long, Z Li, S Wan, G Wang, Y Yu, J Hou, X Wu*, J Zhang*, Design, synthesis, biological evaluation and molecular modeling of novel. 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors, Eur J Med Chem, 2018,143:182-199. ；

2. Zhang T#, Tian Y#, Li Z, Liu S, Hu X, Yang Z, Ling X, Liu S*, Zhang J*, Molecular Dynamics Study to Investigate the Dimeric Structure of the Full-Length α-Synuclein in Aqueous Solution. J Chem Inf Model, 2017, 57(9):2281-2293.；

3. Tian Y#, Yu Y#, Shen Y, Wan H, Chang S, Zhang T, Wan S, Zhang J*, Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK, J Chem Inf Model, 2017, 57:977−987.；

4. XY Wu#* ,Y Fu , YY Wang , SH Wan , JJ Zhang*, Computational investigation on inhibition mechanism of BRAFV600E by Vemurafenib (PLX4032) and its analogue PLX4720, Med Chem Res, 2017, 26:390–396. ；

5. Xiaoyun Wu#*, Yuanyuan Wang, Shanhe Wan，Jiajie Zhang*, Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations, J BIOMOL STRUCT DYN, 2017, 2017:e1538.；

6. Fu Y, Wang Y, Wan S, Li Z, Wang G, Zhang J*, Wu X*, Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies, Molecules, 2017, 22: 542. ；

7. Wu X#*, Fu Y, Wang Y, Wan S, Zhang J*, Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations, J Mol Model, 2017, 23:141. ；

8. Yu PJ, Wan LM, Wan SH, Chen WY, Xie H, Meng DM, Zhang JJ*, Xiao XL*, Standardized myrtol attenuates lipopolysaccharide induced acute lung injury in mice, Pharm Biol, 2016,54(12):3211-3216.；

9. Hou J#, Wan S#, Wang G, Zhang T, Li Z, Tian Y, Yu Y, Wu X*, Zhang J*, Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor, Eur J Med Chem, 2016,118:276-289.；

10. Wu X*, Wan S, Wang G, Jin H, Li Z, Tian Y, Zhu Z, Zhang J*, Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2, J Mol Graph Model., 2015,56:103-112.；

11. Tian Y, Shen Y, Zhang X, Ye L, Li Z, Liu Z, Zhang J*, Wu S, Design Some New Type-I c-met Inhibitors Based on Molecular Docking and Topomer CoMFA Research, Mol Inf, 2014, 33:536-543.；

12. Xiaoyun Wu#*, Shanhe Wan, Zhonghuang Li, Lin Yan, Jiajie Zhang*, Shuguang Wu, 3D-QSAR study on 2,3-dihydroimidazo [4,5]-pyridin-2-one derivatives with a meta substitution pattern as V600E BRAF inhibitors, Med Chem Res, 2014,23: 587-602.；

13. Li JR#, Wu N# , Tian YX , Zhang JJ*, Wu SG*, Aminopyridyl/Pyrazinyl Spiro[indoline-3,4′-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors, ACS Med Chem Lett, 2013, 4 (8):1948-5875.；

14. Ye, LB#, Ou XM#, Tian YX, Yu BW, Luo Y, Feng BH, Lin H , Zhang JJ*, Wu SG*, Indazoles as potential c-met inhibitors: Design, synthesis and molecular docking studies, Eur J Med Chem, 2013,65:112-8. ；

15. Wu XY#*, Wan SH, Zhang JJ*, Three Dimensional Quantitative Structure-Activity Relationship of 5H-Pyrido[4,3-b] indol-4-carboxamide JAK2 Inhibitors, Int J Mol Sci. 2013,14(6):12037-53. ；

16. Wu XY#*, Chen WH#, Wu SG, Tian YX, Zhang JJ*, Pyrrolo[3,2-d]pyrimidine Derivatives as Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies, Int J Mol Sci, 2012,13(2): 2387-2404. ；

17. Ye LB#, Tian YX#, Li ZH, Jin H, Zhu ZG, Wan SH, Zhang JY, Yu PJ, Zhang JJ*, Wu SG*，Design, synthesis and molecular docking studies of some novel spiro[indoline-3,4’- piperidine]-2- ones as potential c-met inhibitors, Eur J Med Chem, 2012, 50:370-375. ；

18. Tian YX, Xu J, Li ZH, Zhu ZG, Zhang JJ*, Wu SG, Combined 3D-QSAR and Docking Modeling Study on Indolocarbazole Series Compounds as Tie-2 Inhibitors, Int J Mol Sci, 2011, 12(8):5080-5097. ；

19. Lianbao Ye, Yuanxin Tian, Zhonghuang Li, Jia-Jie Zhang*, Shuguang Wu*, Design and Synthesis of Some Novel 3,4,5-Tetrahydro-1H-pyrido [4,3-b] indoles as Potential c-Met Inhibitors, Helvetica Chimica Acta, 2012 (95):320-326. ；

20. Jun-Yan Zhang#, Hong Jin#, Guang-Fa Wang, Peng-Jiu Yu, Shao-Yu Wu, Zheng-Guang Zhu, Zhong-Huang Li, Yuan-Xin Tian, Wei Xu, Jia-Jie Zhang*, Shu-Guang Wu*, Methyl-1-hydroxy-2-naphthoate, a novel naphthol derivative, inhibits lipopolysaccharide-induced inflammatory response in macrophages via suppression of NF-κB, JNK and p38 MAPK pathways, Inflamm Res, 2011, 60: 851-859. ；

21. Yuanxin Tian, Jian Xu, Zhonghuang Li, Zhengguang Zhu, Jia-Jie Zhang* , Shu-Guang Wu*, Combined 3D-QSAR and Docking Modeling Study on Indolocarbazole Series Compounds as Tie-2 Inhibitors, Int J Mol Sci, 2011, 12(8):5080-5097.；

22. Wu SY#, Wang GF#, Liu ZQ, Rao JJ, Lü L, Xu W, Wu SG*, Zhang JJ*, Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin,  Acta Pharmacol Sin, 2009,30(2):202-8.；

23. Wang GF#, Wu SY#, Rao JJ, Lü L, Xu W, PANG JX，Liu ZQ, Wu SG*, Zhang JJ*, Genipin inhibits endothelial exocytosis via nitric oxide in cultured human umbilical vein endothelial cells, Acta Pharmacol Sin, 2009, 30(5):589-596.

 

专利

1. 1-(2-氨基吡啶-4-基)-3-哌啶甲酰胺衍生物及其合成方法和应用。申请号:201710237252.X；

2. 3-(1-(氨基吡啶氧基乙基)苯甲酰胺衍生物及其合成方法和应用。申请号:201710059925.7；

3. 6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用。申请号:201610156123.3；

4. 2-氨基吡咯并[1,2-f][1,2,4]三嗪类化合物、合成方法及应用。申请号:201510259005.0，授权；

5. 一种螺三环类化合物及其制备方法、以含该类化合物的药物组合物及其应用。申请号:201110328838.X，授权；

6. 一种稠三环类化合物及其制备方法、以含该类化合物的药物组合物及其应用。申请号:201110327893.7，授权；

7. 一种螺环化合物及其制备方法和应用。申请号:201010205187.0，授权；

8. 一种四氢吡啶并吲哚类化合物及其制备方法和应用。申请号:201010205202.1，授权；

9. 一种咪唑并吡啶类化合物。申请号:200910128203.8，授权